IDC 331
Alternative Names: IDC-331Latest Information Update: 22 Sep 2023
At a glance
- Originator Prestige BioPharma
- Class Antibodies; Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 11 Sep 2023 Early research in Solid tumours in Singapore (Parenteral), prior to September 2023 (Prestige Biopharma pipeline, September 2023)